Structures by: Boulhaoua M.
Total: 20
1-Methyl-4-phenyl-3-[4-(trifluoromethyl)phenyl]-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine
C19H13F3N4
IUCrData (2018) 3, 6 x180875
a=15.0553(10)Å b=15.7338(12)Å c=6.9701(5)Å
α=90° β=99.540(4)° γ=90°
1-Methyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4(5<i>H</i>)-one
C6H6N4O
IUCrData (2018) 3, 3 x180483
a=3.8342(2)Å b=5.5701(3)Å c=15.0346(9)Å
α=93.396(4)° β=92.812(4)° γ=92.361(4)°
1-Benzyl-5-nitro-1<i>H</i>-indazole
C14H11N3O2
IUCrData (2016) 1, 3 x160485
a=14.0236(3)Å b=6.99760(10)Å c=25.3551(5)Å
α=90° β=105.2450(10)° γ=90°
5-Nitro-1-(prop-2-yn-1-yl)-1<i>H</i>-indazole
C10H7N3O2
IUCrData (2016) 1, 3 x160480
a=4.01050(10)Å b=21.0705(7)Å c=10.7451(4)Å
α=90° β=96.323(2)° γ=90°
1-Ethyl-5-nitro-1<i>H</i>-indazole
C9H9N3O2
IUCrData (2016) 1, 4 x160567
a=6.75630(10)Å b=11.2307(2)Å c=11.7323(3)Å
α=90° β=90° γ=90°
1-Benzyl-4-phenyl-1<i>H</i>-1,5-benzodiazepin-2(3<i>H</i>)-one
C22H18N2O
IUCrData (2016) 1, 12 x161988
a=14.6973(7)Å b=5.9179(3)Å c=19.8537(9)Å
α=90° β=93.4610(10)° γ=90°
3-Chloro-6-nitro-1-[(1-octyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-1<i>H</i>-indazole
C18H23ClN6O2
IUCrData (2017) 2, 2 x170146
a=25.3512(9)Å b=14.9091(5)Å c=10.7525(3)Å
α=90° β=101.725(2)° γ=90°
3-Phenylisoxazolin-5-one
C9H7NO2
IUCrData (2017) 2, 1 x170032
a=9.9869(6)Å b=5.3008(3)Å c=13.9874(9)Å
α=90° β=93.106(2)° γ=90°
2-(2-Amino-5-methyl-1,2,4-triazolo[1,5-<i>a</i>]pyrimidin-7-yl)acetohydrazide monohydrate
C8H11N7O,H2O
IUCrData (2016) 1, 6 x160870
a=7.2648(3)Å b=8.7228(4)Å c=8.9297(4)Å
α=82.834(2)° β=71.465(2)° γ=85.4780(10)°
1-(5-Nitro-1<i>H</i>-indazol-1-yl)ethanone
C9H7N3O3
IUCrData (2016) 1, 6 x160939
a=7.6004(3)Å b=7.9200(3)Å c=9.3621(3)Å
α=113.0200(10)° β=91.404(2)° γ=118.350(2)°
(3<i>S</i>)-3,8-Dibromo-4-phenyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazapin-2-one
C15H10Br2N2O
IUCrData (2017) 2, 3 x170389
a=7.8931(8)Å b=9.9295(10)Å c=10.2411(11)Å
α=101.7510(10)° β=105.968(2)° γ=109.4820(10)°
3-Acetyl-2-methyl-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one
C11H10N2O2
IUCrData (2017) 2, 7 x170991
a=3.7716(6)Å b=10.3959(15)Å c=12.3280(18)Å
α=78.017(2)° β=83.431(2)° γ=81.266(2)°
(2<i>Z</i>)-2-(4-Chlorobenzylidene)-4-[2-(2-oxooxazoliden-3-yl)ethyl]-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-3-one
C20H17ClN2O3S
IUCrData (2017) 2, 5 x170646
a=6.2315(3)Å b=15.5466(8)Å c=18.9162(10)Å
α=90° β=98.8450(10)° γ=90°
5-Nitro-1-(prop-2-en-1-yl)-1<i>H</i>-indazole
C10H9N3O2
IUCrData (2017) 2, 7 x171091
a=6.9549(5)Å b=11.6778(9)Å c=12.2165(9)Å
α=90° β=90° γ=90°
2-(2-Oxo-4-phenyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-1-yl)acetic acid
C17H14N2O3
IUCrData (2017) 2, 1 x170120
a=17.9752(8)Å b=17.4403(8)Å c=9.2472(4)Å
α=90° β=102.8920(10)° γ=90°
2-(3-Bromo-5-nitro-1<i>H</i>-indazol-1-yl)-1-phenylethanone
C15H10BrN3O3
IUCrData (2017) 2, 4 x170559
a=13.2690(6)Å b=15.6721(7)Å c=7.2136(3)Å
α=90° β=99.029(2)° γ=90°
(2<i>Z</i>)-2-Benzylidene-4-[(1-benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-3-one
C25H20N4OS
IUCrData (2016) 1, 11 x161823
a=21.8833(8)Å b=5.7007(2)Å c=16.8054(6)Å
α=90° β=100.2340(10)° γ=90°
5-[(5-Nitro-1<i>H</i>-indazol-1-yl)methyl]-3-phenyl-4,5-dihydroisoxazole
C17H14N4O3
Acta Crystallographica Section E (2019) 75, 1 71-74
a=7.8595(4)Å b=11.8831(7)Å c=15.5716(9)Å
α=90° β=101.8530(10)° γ=90°
3-(4-Methoxyphenyl)-1-methyl-4-phenyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine
C19H16N4O
Acta Crystallographica Section E (2019) 75, 5 638-641
a=6.5227(3)Å b=7.8979(4)Å c=30.7774(15)Å
α=90° β=95.389(2)° γ=90°
Triethyl 2-(5-nitro-2<i>H</i>-indazol-2-yl)propane-1,2,3-tricarboxylate
C19H23N3O8
Acta Crystallographica Section E (2015) 71, 10 o780-o781
a=13.4555(4)Å b=18.6185(6)Å c=8.5258(3)Å
α=90° β=104.6030(10)° γ=90°